Facet Utilization Up From 2000 to 2006, Plateaued to 2012

This article originally appeared here.
Share this content:
Facet Utilization Up From 2000 to 2006, Plateaued to 2012
Facet Utilization Up From 2000 to 2006, Plateaued to 2012

FRIDAY, Sept. 23, 2016 (HealthDay News) -- Bundling of the Current Procedural Terminology (CPT) codes for facet injections with image guidance and limiting billing to a maximum of three levels, implemented in 2010, correlated with a large decrease in use of facet injections, according to a study published in the September issue of The Spine Journal.

In a retrospective study, William Jeremy Beckworth, M.D., from Emory University in Atlanta, and colleagues examined whether the CPT code changes correlated with decreased utilization of facet injections. Data were obtained for 100 percent Medicare Part B claims submitted for facet joint injections from 2000 to 2012.

The researchers observed an increase in facet utilization from 2000 to 2012, with an average growth rate of 11 and 15 percent per year for lumbosacral facet injections and cervical-thoracic facet injections (per 100,000 Medicare enrollees). From 2000 to 2006 the largest growth occurred (25 and 32 percent growth per year for lumbosacral and cervical-thoracic injections, respectively, per 100,000 Medicare enrollees). From 2007 to 2012 this leveled off (−3 and −2 percent per year, respectively). 2010 saw the biggest decrease in these procedures, with decreases of 14 and 15 percent for lumbosacral and cervical-thoracic facet injections, respectively (per 100,000 Medicare beneficiaries).

"Facet injection utilization notably increased from 2000 to 2006 but began to level off from 2007 to 2012," the authors write.

One author disclosed financial ties to Mesoblast.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

ASH: Synthetic Blood Cell Passes Proof-of-Concept Testing

Synthetic product made from purified human hemoglobin proteins coated with a synthetic polymer

Fewer School Shootings in States With Tighter Gun Laws

Fewer School Shootings in States With Tighter Gun ...

Study also found that states that spent more money on mental health care, education saw less violence

SABCS: No Survival Benefit Seen for Letrozole Beyond Five Years

SABCS: No Survival Benefit Seen for Letrozole Beyond ...

Study found women who continued with letrozole did experience other benefits, however

is free, fast, and customized just for you!

Already a member?

Sign In Now »